Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons

Journal of Psychopharmacology
R GhanbariPierre Blier

Abstract

Clinical studies indicate that addition of bupropion to selective serotonin (5-HT) reuptake inhibitors (SSRIs) provides incremental benefit over SSRI monotherapy in depression. This study was designed to investigate the effects of co-administration of bupropion with escitalopram on the firing rate of 5-HT and norepinephrine (NE) neurons in anesthetized rats. Escitalopram (10 mg/kg/day x 2 days), given via subcutaneously (s.c.) implanted minipumps, decreased the firing of 5-HT and NE neurons by 70% and 55%, respectively. The firing of 5-HT neurons, unlike that of NE neurons, recovered after the 14-day escitalopram regimen. Bupropion, injected once daily (30 mg/kg/day, s.c. x 2 days), did not increase 5-HT firing but decreased that of NE by 55%. After 14 days of repeated bupropion administration, 5-HT firing was increased by 50%, and NE firing was back to baseline. Co-administration of escitalopram and bupropion doubled 5-HT firing after 2 and 14 days, whereas NE neurons were inhibited by 60% after 2 days, but partially recovered after 14 days. The responsiveness of 5-HT(1A) autoreceptors was significantly attenuated in the combination-treated rats after 2 days, indicating an early desensitization. These results provide support f...Continue Reading

References

Apr 16, 1998·European Journal of Pharmacology·M TatsumiE Richelson
Apr 3, 1999·British Journal of Pharmacology·S T SzaboP Blier
Jul 20, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·D MischoulonM Fava
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
May 3, 2001·Bipolar Disorders·J J DalyH A Sackeim
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Steven T Szabo, Pierre Blier
Aug 20, 2002·Psychopharmacology·Jeffrey H MeyerSylvain Houle
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Akira KugayaRobert B Innis
Jun 27, 2003·Journal of Clinical Psychopharmacology·Gabriella GobbiPierre Blier
Oct 11, 2003·Biological Psychiatry·Susan M Learned-CoughlinBengt Långstrom
May 26, 2004·Biological Psychiatry·Matthew A SeagerKurt Rasmussen
Nov 10, 2004·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Paul R Albert, Sylvie Lemonde
Feb 11, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mostafa El MansariNasser Haddjeri
Oct 11, 2005·Journal of Affective Disorders·Miklós ArgyelánLászló Pávics
Mar 24, 2006·The New England Journal of Medicine·Madhukar H TrivediUNKNOWN STAR*D Study Team
Apr 29, 2006·Journal of Psychopharmacology·Charles DeBattista
Sep 29, 2006·The Journal of Pharmacology and Experimental Therapeutics·Teresa K AmanSamir Haj-Dahmane

❮ Previous
Next ❯

Citations

Aug 9, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Franck ChenuPierre Blier
Apr 26, 2013·ACS Chemical Neuroscience·Hongyan YangAnne M Andrews
Dec 19, 2014·The International Journal of Neuropsychopharmacology·Mostafa El MansariPierre Blier
Jan 31, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Natalia JaworskaVerner Knott
Oct 9, 2013·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Natalia Jaworska, Andrea Protzner
May 13, 2019·Experimental Brain Research·Paul J Fitzgerald, Brendon O Watson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.